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Abstract
Background: To evaluate the current status of prospective interventional clinical trials that includes brachytherapy
(BT) procedures.
Methods: The records of 175,538 (100 %) clinical trials registered at ClinicalTrials.gov were downloaded on September
2014 and a database was established. Trials using BT as an intervention were identified for further analyses. The selected
trials were manually categorized according to indication(s), BT source, applied dose rate, primary sponsor type, location,
protocol initiator and funding source. We analyzed trials across 8 available trial protocol elements registered within the
database.
Results: In total 245 clinical trials were identified, 147 with BT as primary investigated treatment modality and 98 that
included BT as an optional treatment component or as part of the standard treatment. Academic centers were the most
frequent protocol initiators in trials where BT was the primary investigational treatment modality (p< 0.01). High dose rate
(HDR) BT was the most frequently investigated type of BT dose rate (46.3 %) followed by low dose rate (LDR) (42.0 %).
Prostate was the most frequently investigated tumor entity in trials with BT as the primary treatment modality (40.1 %)
followed by breast cancer (17.0 %). BT was rarely the primary investigated treatment modality for cervical cancer (6.8 %).
Conclusion: Most clinical trials using BT are predominantly in early phases, investigator-initiated and with low accrual
numbers. Current investigational activities that include BT mainly focus on prostate and breast cancers. Important
questions concerning the optimal usage of BT will not be answered in the near future.
Keywords: Brachytherapy, Clinicaltrials.gov, Interventional clinical trials
Introduction
Radiotherapy (RT) was first applied in medicine at the
beginning of the 20th century [1]. Nowadays RT plays
an ever increasing role in the treatment of multiple
tumor entities, with more than 50 % of all cancer pa-
tients receiving some sort of RT, in curative or palliative
intent, during the course of their disease [2]. Brachyther-
apy (BT) has been a well-established modality, mainly
due to its high conformity and possibility of sparing
organs-at-risk [3]. The field of RT has recently seen the
introduction of several new technologies in everyday
praxis. However, the utilization of newer technologies is
not always accompanied with a high level of evidence
[4]. Furthermore, little is known about ongoing pro-
spective research in RT. This holds true for BT as well.
Several clinical trial registries were established during
the past decade. Trial registration is being regulated with
European and US federal laws as well as international
conventions (World Health Organization, WHO) [5, 6].
Registration of all interventional clinical trials is obliga-
tory in the European Union (EU) and the United States
(US) and is demanded by an international consortium of
medical journal editors [7, 8]. ClinicalTrials.gov is the
largest clinical trial registry with over 190,000 registered
trials and a high weekly growth rate of new registrations.
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The registration process and its potential for an in-depth
analysis of the clinical trials landscape is well described
in the literature [6, 9–11]. Several studies evaluating dif-
ferent disease groups have already been published [12–14].
Goal of this study was to evaluate the present land-
scape of interventional clinical trials that include BT
alone or as part of a multimodal approach.
Material and methodes
Data acquisition
The xml [15] records of 175,538 (100 %) clinical trials
registered at ClinicalTrials.gov were downloaded on
September 29th 2014 and a database was created. The
established database was searched using MeSH terms
and a list of keywords. In total, 6389 (3.6 %) trials were
identified and selected for further manual review with
4897 (2.8 %) being radiotherapy related. We stratified
trials according to the utilized radiotherapy technique.
BT was part of the investigated procedure in 268 (0.1 %)
trials. Suspended, terminated or withdrawn trials were
excluded from further analysis (n = 23). In total, 245 tri-
als were identified. The trial selection process is shown
in Fig. 1.
We categorized the trials according to the role of
BT procedures into two categories: 1. trials with BT
in focus as primary investigated treatment modality
Fig. 1 Trial selection process
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(BF, n = 147); 2. trials in which external beam radio-
therapy (EBRT) was combined with BT and trials,
where the usage of BT was optional, the “other trials”
Group (OT, n = 98).
Trials were manually categorized according to the in-
vestigated conditions based on the International Classifi-
cation of Diseases (ICD-10).
We classified the primary sponsor and collaborators in
the following categories: National Institute of Health -
USA (NIH), Academic Institutions, Cooperative Groups
and Industry. The primary sponsor field was used to
categorize the protocol initiator.
Probable funding source (source of monetary support)
was determined based on a modified methodology de-
scribed in the work of Hirsch et al. and Califf et al. [16, 17]
(Appendix).
Basic information of the selected trials, including the
protocol initiator, funding source, BT dose rate type,
countries where the trials were conducted and bodily
organ investigated are presented in Table 1.
Table 1 Protocol initiator, source of founding, nature of BDR, organ and state
All BF OT p value
(n = 245, 100 %) (n = 147, 60 %)c (n = 98, 40 %)d
Protocol initiator
Academic 176 (71.8 %) 120 (81.6 %) 56 (57.1 %) <0.001
Collaborative Groups 42 (17.1 %) 11 (7.5 %) 31 (31.6 %)
Industry 15 (6.1 %) 13 (8.8 %) 2 (2.0 %)
NIH 12 (4.9 %) 3 (2.0 %) 9 (9.2 %)
Source of funding
Academic 145 (59.2 %) 99 (67.3 %) 46 (46.9 %) <0.001
Collaborative Groups 13 (5.3 %) 2 (1.4 %) 11 (11.2 %)
Industry 30 (12.2 %) 25 (17.0 %) 5 (5.1 %)
NIH 56 (22.9 %) 20 (13.6 %) 36 (36.7 %)
Public-private part. 1 (0.4 %) 1 (0.7 %) 0 (0.0 %)
Type of BDRa
Not definedb 83 (33.9 %) 30 (20.4 %) 53 (54.1 %) <0.001
HDR 75 (46.3 %) 53 (45.3 %) 22 (48.9 %) 0.001
HDR/LDR 16 (9.9 %) 6 (5.1 %) 10 (22.2 %)
HDR/PDR 2 (1.2 %) 2 (1.7 %) 0 (0.0 %)
LDR 68 (42.0 %) 56 (47.9 %) 12 (26.7 %)
PDR 1 (0.6 %) 0 (0.0 %) 1 (2.2 %)
Country
USA 144 (58.8 %) 85 (57.8 %) 59 (60.2 %) 0.219
Canada 27 (11.0 %) 20 (13.6 %) 7 (7.1 %)
France 10 (4.1 %) 6 (4.1 %) 4 (4.1 %)
China 10 (4.1 %) 7 (4.8 %) 3 (3.1 %)
Germany 10 (4.1 %) 8 (5.4 %) 2 (2.0 %)
Other 44 (18.0 %) 21 (14.3 %) 23 (23.5 %)
Organ
Prostate 80 (32.7 %) 59 (40.1 %) 21 (21.4 %) <0.001
Cervix uteri 54 (22.0 %) 10 (6.8 %) 44 (44.9 %)
Breast 29 (11.8 %) 25 (17.0 %) 4 (4.1 %)
Uterus 14 (5.7 %) 5 (3.4 %) 9 (9.2 %)
Other 68 (27.8 %) 48 (32.7 %) 20 (20.4 %)
aBDR brachytherapy dose rate, HDR high dose rate, LDR low dose rate, PDR pulse dose rate
bPercentage of total number per column
cBrachytherapy in focus
dOther trials
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Statistical analysis
Descriptive data are presented in numbers and percent-
ages. Differences between the two groups were analyzed
using the Pearson chi-square test and Chi-Square test.
Statistical analysis was conducted using the SPSS soft-
ware version 20.0 (SPSS Inc., Chicago, IL, USA). All p
values less than 0.05 were considered significant.
Results
Our study included 245 clinical trials, 147 trials with BT
in focus (BF group, 60 %) and 98 other trials (OT group,
40 %).
Academy was the most frequent protocol initiator and
source of funding. Focused on the protocol initiator,
academy is dominant in the BF group but equal with
NIH in the OT group. Collaborative groups have a
higher percentage in other trials, compared to BT. The
type of BT dose rate (BDR) differs significantly in the BF
group as compared to the OT group. Missing data (not
defined) is twofold higher in the OT group. Prostate is
the most researched treated site in the BF group,
whereas Cervix Uteri is the most studied site in the OT
group. No significant differences were seen between all
trials, BF and OT groups according to the countries
where the trials were conducted (p: 0.355) (Table 1).
When comparing data availability, registered informa-
tion, such as trial phase, is predominantly missing from
the BF Group, whereas in all other investigated parame-
ters the OT group has a higher data unavailability
(Tables 2 and 3). The groups differ in trial phase, end-
point classification and allocation. Phase 2 trials are the
most common in both the BF and OT groups (41.6 and
36.4 %, respectively) followed by phase 3 trials (23 and
33 %, respectively). The groups differ in the percentage
of phase 1 and phase 4 trials, but have a similar distribu-
tion of trial arms, enrollment and intervention model
(Table 2).
Based on our results, shown in Table 3, the examined
groups significantly differ in trial allocation. Randomized
trials are more frequent in the OT group, whereas the
BF group has mostly non-randomized trials. In the BF
group, trials are mostly in a recruiting stage, while in the
OT group they are mostly completed.
Focusing on the BF group alone (Table 4), there is a
significant difference between the investigated organs,
only during the last changed period. Although the me-
dian duration to the primary outcome and time to com-
pletion differs between organs, this difference is not
statistically significant likely due to the high variability
and small sample sizes.
Discussion
We have shown that BT is rarely evaluated in prospect-
ive clinical trials either as a single treatment modality or
combined with EBRT. There are several possible expla-
nations for this occurrence. BT is a demanding discip-
line, because of the need for experienced personnel and
the specialized equipment required. Even in centers with
available infrastructure, BT is most often used for the
treatment of gynecological malignancies and rarely used
for other tumor entities [18–21]. Furthermore, new
highly conformal EBRT techniques are gaining in popu-
larity, although their usage is still not based on high
quality evidence [22–24]. This, in turn, potentially af-
fected and caused the decline of BT as a viable treatment
modality. Unfortunately, the current trend continues
and is even seen in tumor entities where BT is consid-
ered mandatory [25, 26]. All of the above makes patient
accrual difficult.
Differences between the BF and OT groups are seen in
protocol development and trial funding. 81.6 % of initi-
ated protocols in BF group and 57.1 % in the OT group
have academic institutions as a primary funding source
and protocol initiators. There appears to be limited
interest from the National Institute of Health – USA
(NIH), the industry and collaborative groups. This effect-
ively shifts the monetary burden to academic institu-
tions, with little support from the industry or NIH.
Compared to the general oncological landscape of trial
funding [17], we see that 41.8 % of trials were primarily
industry-funded, 15.3 % government-funded (NIH) and
42.9 % from predominantly academic sources.
Most trials were initiated in the US (58.8 %), followed
by Canada (11.0 %) and France (4.1 %). A possible ex-
planation is that registration of trials in the Clinical-
Trials.gov registry is obligatory in the US. Nevertheless,
the ClinicalTrials.gov registry encompasses more than
70 % of all trials registered in the primary WHO regis-
try. Also the uneven distribution could be a result of
the lower expenditure for healthcare research in the EU
[27, 28].
A major problem of this study is the low data availabil-
ity. Data availability appears higher in trials initiated and
sponsored by academic institutions and in BT focused
trials. Individual investigators or institutions seem more
eager to submit data during the registration process.
However, in the work from Califf et al. it is shown that
data availability shows a positive time trend, with more
data becoming available as registration progresses [16].
In addition some data are more accurate within the
database as compared to the published data [29, 30].
Sponsors should be motivated to submit accurate and
updated data into the registries.
Further discussion-diseases
Cervical cancer (CCa)
Although CCa is the tumor entity most commonly
treated with combined EBRT and BT in clinical practice,
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prospective trials investigating the role of BT in the
treatment of CCa are surprisingly rare, especially when
compared to the number of prostate and breast cancer
trials [20, 31]. There is a declining trend in BT usage as
part of the standard treatment of CCa, showing a de-
crease from 83 % in 1988 to 58 % in 2009 [25]. One pos-
sible explanation may be the introduction of highly
conformal EBRT. Furthermore the limited interest could
Table 2 Trial characteristic
All BF OT Availability*
(n = 245, 100 %) (n = 147, 60 %)b (n = 98, 40 %)c BF vs OT**
Trial phase
Data not availablea 44 (18.0 %) 34 (23.1 %) 10 (10.2 %) 0.010*
Phase 0 1 (0.5 %) 1 (0.9 %) 0 (0.0 %) 0.005**
Phase 1 33 (16.4 %) 13 (11.5 %) 20 (22.7 %)
Phase 1/Phase 2 16 (8.0 %) 10 (8.8 %) 6 (6.8 %)
Phase 2 79 (39.3 %) 47 (41.6 %) 32 (36.4 %)
Phase 2/Phase 3 4 (2.0 %) 4 (3.5 %) 0 (0.0 %)
Phase 3 55 (27.4 %) 26 (23.0 % 29 (33.0 %)
Phase 4 13 (6.5 %) 12 (10.6 %) 1 (1.1 %)
Number of trial arms
Data not availablea 48 (19.6 %) 28 (19.0 %) 20 (20.4 %) 0.793*
1 110 (55.8 %) 71 (59.7 %) 39 (50.0 %) 0.081**
2 74 (37.6 %) 43 (36.1 %) 31 (39.7 %)
3 6 (3.0 %) 2 (1.7 %) 4 (5.1 %)
4 6 (3.0 %) 3 (2.5 %) 3 (3.8 %)
5 1 (0.5 %) 0 (0.0 %) 1 (1.3 %)
Enrollment (No of patients)
Data not availablea 2 (0.8 %) 9 (6.1 %) 7 (7.1 %) 0.751*
1–50 105 (43.2 %) 65 (44.8 %) 40 (40.8 %) 0.184**
51–100 40 (16.5 %) 26 (17.9 %) 14 (14.3 %)
101–200 27 (11.1 %) 15 (10.3 %) 12 (12.2 %)
201–500 30 (12.3 %) 20 (13.8 %) 10 (10.2 %)
>500 41 (16.9 %) 19 (13.1 %) 22 (22.4 %)
Intervention model
Data not availablea 40 (16.3 %) 18 (12.2 %) 22 (22.4 %) 0.034*
Single Group Assignment 124 (60.5 %) 84 (65.1 %) 40 (52.6 %) 0.075**
Parallel Assignment 78 (38.0 %) 42 (32.6 %) 36 (47.4 %)
Factorial Assignment 2 (1.0 %) 2 (1.6 %) 0 (0 %)
Crossover Assignment 1 (0.5 %) 1 (0.8 %) 0 (0 %)
Endpoint classification
Data not availablea 74 (30.2 %) 38 (25.9 %) 36 (36.7 %) 0.069*
Safety Study 18 (10.5 %) 5 (4.6 %) 13 (21.0 %) 0.002**
Efficacy Study 60 (35.1 %) 42 (38.5 %) 18 (29.0 %)
Safety/Efficacy Study 91 (53.2 %) 61 (56.0 %) 30 (48.4 %)
Bio-equivalence Study 1 (0.6 %) 1 (0.9 %) 0 (0.0 %)
Pharmacodynamics Study 1 (0.6 %) 0 (0 %) 1 (1.6 %)
aPercents of total number per column
bBrachytherapy in focus
cOther trials
*p value for availability of data between groups
**p value for test between BF and OT (without unavilable data)
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be a result of the low incidence of advanced CCa in de-
veloped countries, where the necessary equipment, infra-
structure and funds are available. This leads to slower
patient accrual and limited interest from the scientific
community. Most registered CCa trials evaluate the
different chemotherapeutical approaches where radio-
therapy is only part of the standard treatment. Trials
concentrated on BT alone are early phase, evaluating
mostly different forms of MRI or PET image guidance
with toxicity evaluation as primary endpoints
(NCT00938106, NCT01399658 and NCT01899404).
It seems that the utilization of newer techniques in
form of image guided BT (IGBT) results in a significant
improvement in local control of up to 95 % [32–36].
These results are currently under evaluation through the
EMBRACE trial (NCT00920920). EMBRACE is an ob-
servational clinical study aiming to recruit more than
600 patients. Primary endpoint is local control and treat-
ment morbidity at 5 years. The initial results are already
available, with reports of toxicity and quality of life
issues [37–39]. The final results in regard to local con-
trol and survival are still pending.
Evaluating the toxicities of the combined treatment with
EBRT and BT is of special concern. The contribution of
BT to healthy tissue total dose is hard to measure. Latest
reports regarding utilization of IGBT combined with 3D
conformal EBRT show discouraging results regarding
quality of life (QOL) [40]. This suggests that higher con-
formity of IGBT alone has no benefit in terms of QOL
and further evaluation as well as optimization of the com-
bined approach is needed.
Data from more conformal EBRT (IMRT, VMAT, helical)
combined with IGBT are limited. The possibility of EBRT
dose escalation for the primary tumor, parametrial as well
as for lymphonodal disease is well described in the litera-
ture [41, 42]. Dose escalated EBRT for treating local disease
may be an option, especially in institutions lacking the re-
quired equipment or experience for conducting IGBT.
EBRT may help in covering parametrial disease, lym-
phonodal disease or high-risk tumor area not accessible
Table 3 Trial characteristics-continued
All BF OT Availability*
(n = 245, 100 %) (n = 147, 60 %)b (n = 98, 40 %)c BF vs OT**
Primary purpose
Data not availablea 7 (2.9 %) 4 (2.7 %) 3 (3.1 %) 1.000*
Treatment 214 (89.9 %) 126 (88.1 %) 88 (92.6 %) 0.550**
Supportive Care 8 (3.4 %) 6 (4.2 %) 2 (2.1 %)
Diagnostic 9 (3.8 %) 6 (4.2 %) 3 (3.2 %)
Health Services Res. 3 (1.3 %) 3 (2.1 %) 0 (0 %)
Prevention 4 (1.7 %) 2 (1.4 %) 2 (2.1 %
Masking
Data not availablea 37 (15.1 %) 19 (12.9 %) 18 (18.4 %) 0.244*
Open Label 195 (93.8 %) 117 (91.4 %) 78 (97.5 %) 0.105**
Double-Blind 6 (2.9 %) 4 (3.1 %) 2 (2.5 %)
Single Blind 7 (3.4 %) 7 (5.5 %) 0 (0 %)
Allocation
Data not availablea 111 (45.3 %) 65 (44.2 %) 46 (46.9 %) 0.675*
Non-Randomized 44 (32.8 %) 31 (37.8 %) 13 (25.0 %) 0.124**
Randomized 90 (67.2 %) 51 (62.2 %) 39 (75.0 %)
Overall
Active, not recruiting 52 (21.2 %) 34 (23.1 %) 18 (18.4 %) 0.075**
Completed 83 (33.9 %) 40 (27.2 %) 43 (43.9 %)
Recruiting 96 (39.2 %) 62 (42.2 %) 34 (34.7 %)
Not yet recruiting 13 (5.3 %) 10 (6.8 %) 3 (3.1 %)
Enrolling by invitation 1 (0.4 %) 1 (0.7 %) 0 (0 %)
aPercentage of total number per column
bBrachytherapy in focus
cOther trials
*p value for availability of data between groups
**p value for test between BF and OT (without unavilable data)
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without needle insertion. Such a concept is currently be-
ing prospectively evaluated through a phase I/II trial -
NCT01793701. Nevertheless, the authors do not suggest
that EBRT could replace BT completely.
It is currently unclear which treatment modality
(EBRT or BT) contributes more to the applied dosage to
organs at risk and consequently to treatment induced
toxicity. The combined dose distribution is hard to
measure.
Endometrial cancer (ECa)
ECa is the most common gynecological malignancy in
the western world with most cases being diagnosed in
an early stage [43]. The current role of adjuvant RT in
the treatment of endometrial cancer is well described in
the ASTRO evidence based guidelines [44]. Sorbe et al
[45] compared intravaginal BT vs surgery alone for low
risk endometrial cancer on 645 patients. The influence
on loco-regional recurrence was limited, with OS and
overall recurrence rate similar in both researched groups
[45]. In its early stages endometrial cancer not receiving
adjuvant RT most commonly recurs in the area of the
vaginal cuff [46]. The role of postoperative RT for high-
intermediate risk endometrial cancer in patients older
than 60 years was determined through the PORTEC-2
trial (NCT00376844). The trial shows similar results be-
tween EBRT and BT alone for patients with intermediate
risk grade 1 disease. However, the results cannot be ap-
plied to grade 2 and 3 disease due to the limited number
of patients in the trial. Similar results in medium risk
endometrial cancer were reproduced by Sorbe B et al
[47], where the combined EBRT and BT shows no differ-
ence in survival but a significantly higher toxicity [47].
The value of adjuvant therapy and the best treatment mo-
dality for high risk stage I and stage II disease should be
clarified through the GOG-0249 Trial (NCT00807768).
This is a randomized phase III trial comparing adjuvant
3D or IMRT (25–28 fractions) versus HDR or LDR BT
combined with carboplatin/paclitaxel chemotherapy. Pri-
mary endpoint is recurrence free survival with a planned
total accrual number of 562 patients and an estimated
final data collection date for the primary outcome
Table 4 Organ in BF group
BF group Prostate (n = 80, %) Cervix uteri (n = 54, %) Breast (n = 29, %) Uterus (n = 14, %) Others (n = 68, %) p value
Prim. Completion attribute
Actual 30 (37.5 %) 18 (33.3 %) 13 (44.8 %) 3 (21.4 %) 18 (26.5 %) 0.283a
Anticipated 43 (53.8 %) 29 (53.7 %) 15 (51.7 %) 9 (64.3 %) 36 (52.9 %
None 7 (8.8 %) 7 (13.0 %) 1 (3.4 %) 2 (14.3 %) 14 (20.6 %)
Completion date attribute
Actual 26 (32.5 %) 12 (22.2 %) 8 (27.6 %) 3 (21.4 %) 20 (29.4 %) 0.112a
Anticipated 39 (48.8 %) 19 (35.2 %) 15 (51.7 %) 5 (35.7 %) 24 (35.3 %)
None 15 (18.8 %) 23 (42.6 %) 6 (20.7 %) 6 (42.9 %) 24 (35.3 %)
First received
1999–2004 12 (15.0 %) 11 (20.4 %) 1 (3.4 %) 1 (7.1 %) 19 (27.9 %) <0.001a
2005–2009 29 (36.2 %) 19 (35.2 %) 19 (65.5 %) 10 (71.4 %) 20 (29.4 %)
2010–2015 39 (48.8 %) 24 (44.4 %) 9 (31.0 %) 3 (21.4 %) 29 (42.6 %)
Last changed
2005–2009 4 (5.0 %) 4 (7.4 %) 2 (6.9 %) 0 12 (17.6 %) 0.202a
2010–2015 76 (95.0 %) 50 (92.6 %) 27 (93.1 %) 14 (100 %) 56 (82.4 %)
Primary completion
2000–2004 4 (5.5 %) 0 1 (3.6 %) 0 7 (13.0 %) 0.104a
2005–2009 10 (13.7 %) 10 (21.3 %) 6 (21.4 %) 0 6 (11.1 %)
2010–2015 36 (49.3 %) 27 (57.4 %) 17 (60.7 %) 8 (66.7 %) 28 (51.9 %)
2016+ 23 (31.5 %) 10 (21.3 %) 4 (14.3 %) 4 (33.3 %) 13 (24.1 %)
Completion year
2000–2004 2 (3.0 %) 0 0 0 6 (13.0 %) 0.027a
2005–2009 9 (13.6 %) 9 (27.3 %) 2 (8.3 %) 1 (12.5 %) 9 (19.6 %)
2010–2015 31 (47.0 %) 16 (48.5 %) 11 (45.8 %) 5 (62.5 %) 17 (37.0 %)
2016+ 24 (36.4 %) 8 (24.2 %) 11 (45.8 %) 2 (25.0 %) 14 (30.4 %)
aChi square test
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measure in March 2013. Results were presented in the
form of an abstract on Annual Meeting of the Society of
Gynecologic Oncology (SGO) in Tampa 2014. Both con-
cepts appear to be equivalent with slightly more acute tox-
icities in the chemotherapy arm [48].
EBRT seems to improve survival in some patients.
EBRT is recommended in cases of nodal positivity, in-
volved serosa, parametria or adjacent organs. The ques-
tion that remains is whether or not an additional BT
boost is required. It seems that the incidence of vaginal
recurrence after pelvic RT is low being between 1.6 and
2.3 % for early stage intermediate or high risk disease
[46, 49]. There are currently no randomized trials com-
paring EBRT vs EBRT with BT. A SEER database ana-
lysis suggests that there is a better outcome when a BT
boost is applied [50].
Breast cancer (BCa)
Most trials involving BT procedures focus on partial
breast irradiation (PBI) as an alternative to whole breast
irradiation (WBI). Notable phase II trials are the
NCT00392184 and NCT00977275 whose results provide
a solid basis for clinicians [51–55].
A randomized phase III trial that will hopefully
provide new insights into PBI is registered under
NCT00103181 (A Randomized Phase III Study of Con-
ventional WBI Versus PBI for Stage 0, I, or II BCa). The
trial, initiated by NSABP, and started in March 2005
with a planned total accrual number of 4216 patients.
Overall survival and quality of life are the primary end-
points. However BT was not in focus and the allowed
BT techniques were Mammosite or single catheter de-
vice. Published works from this trial are mostly concen-
trated on EBRT issues [56–58].
More important from a BT perspective is the phase III
trial conducted by the Breast Cancer Working Group of
the GEC-ESTRO with the sponsorship of the German
Cancer Aid, including 16 centers from 7 European coun-
tries and co-chaired by Erlangen and Budapest, the
GEC-ESTRO APBI Trial (NCT00402519). The recently
published 5-year results showed that adjuvant acceler-
ated partial breast irradiation (APBI) using multicatheter
brachytherapy is not inferior to adjuvant WBI with re-
spect to 5-year local control, disease-free survival, and
overall survival [59].
No trials directly comparing different BT approaches
in terms of application technique or fractionation (e.g.,
multi-catheter vs. balloon technique; single fraction vs.
multiple fractions) were detected. It remains unclear,
whether a multicatheter interstitial BT has a superior
cosmetic outcome, indeed the required large sample size
and the long follow-up makes conducting of such a trial
difficult. Furthermore, trials evaluating BT as an alterna-
tive to EBRT boost for patients with high-risk BCa
would be of interest especially if a dose higher than
16 Gy is required. A retrospective trial published by
Knauerhase et al. suggests that the usage of BT may be
beneficial in terms of local control [60].
Prostate cancer (PCa)
PCa is the tumor entity with the most current trials.
There is literature on PCa BT trial results from a time
prior to the era of trial registration, but that would ex-
ceed the scope of this article. The main therapeutic mo-
dalities of BT for PCa can be divided in LDR and HDR,
which can be used as a single modality or combined
with EBRT.
Grimm et al. [61] retrospectively analyzed PCa series
published during 2000–2010 including different treatment
modalities. Bearing in mind the potential biases that are
intrinsic of observational cohorts and problems in directly
comparing different treatment modalities, BT provided
the best biochemical control rates as compared to other
modalities for low-risk disease. For intermediate-risk dis-
ease, the combination of EBRT and BT appeared equiva-
lent to BT alone and superior to EBRT or surgery. For
high-risk patients, combination therapies involving EBRT
and BT with or without androgen deprivation therapy
(ADT) appear superior to more localized treatments such
as seed implants, surgery or EBRT alone.
Probably the first studies in prostate BT were pub-
lished by the Seattle group. Fifteen-year biochemical
relapse-free survival (BRFS) and cause-specific survival
(CSS) exceeded 80 % for localized PCa treated with I125
BT as monotherapy [62]. Excellent results were also seen
using a combination of EBRT and a BT boost with seeds
in different risk groups [63].
In 1995 Martinez et al. began the HDR monotherapy
program at William Beaumont Hospital for low/inter-
mediate risk patients [64], from multi-fraction (4 frac-
tions of 9.5 Gy) to a single fraction of 19 Gy. He used a
α/β ratio of 1.5 to give a BED of approximately 260 Gy.
He compared the results of LDR BT with HDR. At
5 years, there were no differences in overall survival, in
CSS or in BRFS between both groups. There were less
chronic urinary side-effects in the HDR group as well as
lower sexual impotency after treatment.
Tselis et al. has published his experience on HDR
monotherapy for localized PCa, 4 fractions of 9.5 Gy in
two implants [65] with good results. However, treatment
toxicity could be an issue [66].
Galalae et al. used HDR as a boost to EBRT [67].
Long-term outcomes are presented in three prospective
trials in three hospitals: Kiel, William Beaumont and Se-
attle. He concludes that EBRT with HDR-BT produced
excellent long-term outcomes in terms of BRFS, DFS,
and CSS.
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Also Vargas and Martinez published their results of
pelvic EBRT with HDR boost for intermediate and high-
risk PCa [68]. HDR dose fractionation increased pro-
gressively and was divided into two dose levels. The
mean prostate biologic equivalency dose was 88.2 Gy for
the low-dose group and 116.8 Gy for the high-dose
group (α/β = 1.2). They concluded that dose escalation
improved loco-regional control and experienced less bio-
chemical and clinical failures at 5 years.
EBRT followed by BT boost is emerging as an effective
approach for unfavorable-risk PCa after the results of
the ASCENDE-RT trial. A phase II/III trial that accrued
400 patients with high- and intermediate-risk disease.
After receiving whole-pelvis EBRT with 46Gy in 23 frac-
tions, patients underwent random assignment to an I125
LDR-BT boost or to a EBRT boost (32 Gy in 16 frac-
tions). Both arms received ADT for 12 months. BPFS
rates between the LDR-BT and EBRT boost arms were
83.3 versus 62.4 % at 9 years. However LDR-BT was as-
sociated with a significantly greater cumulative incidence
of late grade 3 genitourinary toxicity compared with
EBRT boost (19 vs. 5 %; p < 0.001).
Currently trending is focal radiotherapy in early PCa.
Kovács wrote an excellent review on the topic [69].
Cosset published his results using focal I125 seeds for se-
lected low-risk patients [70]. Focal treatment using BT is
technically feasible however further investigation is
needed in order to assess its definite role in PCa.
Tsikkinis et al [71] has shown that despite a strong on-
going clinical research activity in PCa, only 7 out of 123 on-
going unpublished phase 3 trials are evaluating BT alone or
BT combined with EBRT (NCT01717677, NCT01936883,
NCT00175396, NCT00063882, NCT00247312, and
NCT01839994). This corresponds to published findings
from the SEER Database [72]. The German PREFERE Trial
is a large prospective multicenter trial developed to com-
pare the four possible treatment options (active surveil-
lance, surgery, EBRT and BT) in newly diagnosed low- or
early intermediate-risk patients. In total 7600 patients are
planned to be recruited and final primary outcome measure
is predicted for 2029.
Esophageal cancer (ECa)
ECa remains a tumor entity in need for further therapy
optimization. Combined modality treatments did not
significantly improve the overall outcome of patients
with advanced disease. The standard EBRT dose of
about 50 Gy [73] may be insufficient for effective local
control. Delivering a higher total dose with EBRT is lim-
ited due to its proximity to vital organs (lung, heart, and
spinal cord) and feared toxicity as well as organ move-
ment and tumor CTV both requiring broader planning
margins as compensation [74, 75]. Although a multi-
institutional randomized trial of EBRT with vs without
additional BT boost showed an improved survival in the
BT arm, the proposed concept was not broadly accepted
[76]. The benefit was higher in patients with tumors up
to 5 cm where the 5-year cause specific survival was
64 %. The mentioned trials were conducted prior to the
era of IMRT and IGBT. The trial results were confirmed
through an additional prospective trial from Brunner et
[77]. Current BT trials for ECa are focusing on
palliation.
Head and neck cancer
The field where BT has the greatest potential is head
and neck cancer, either in early stage tumors or as a
boost for locally advanced disease. However, we identi-
fied only 4 trials that included BT in the treatment
protocol and in 2 of them BT was only optional. In one
trial the BT aim was palliation (NCT01086488) and the
second evaluated I125 seed therapy for salivary gland
cancer (NCT02048254). The role of BT in squamous cell
cancer of the head and neck region is currently not be-
ing investigated in any of the identified trials.
Non-malignant diseases
BT plays also a role in non-malignant diseases. An inter-
esting application of BT is in the treatment of pterygia, a
disease most commonly surgically treated with mostly
unsatisfactory results. The safety and efficacy of BT as a
treatment modality was confirmed through a prospective
phase II trial [78]. The mentioned trial was conducted
prior to the era of obligatory registration. Further intri-
guing applications of BT is in the treatment of macular
degeneration (evaluated through NCT00100087 and
NCT01006538), renal denervation (NCT01968785) and
inoperable pituitary macroadenomas (NCT01444209).
Brachytherapy usage is by no means limited to the
above-mentioned tumor entities; well-established brachy-
therapy applications as well as other less frequent indica-
tions have been developed and successfully applied during
recent years. Corresponding clinical trials are provided as
supplementary material (Additional file 1).
Limitations Our analysis is not without limitations. Not
every clinical trial is registered on ClinicalTrials.gov;
other internationally accepted registries do exist and
some trials could be registered elsewhere. Nevertheless,
as ClinicalTrials.gov is the largest trials registry available,
with 52 % of all registered trials non-US-based, our find-
ings provide a representative, if not complete, picture of
current research. Moreover, we cannot exclude the pos-
sibility of errors whereby certain trials were not captured
for the analysis and/or were misclassified during the
selection process. In addition, the data sets for all trials
in the database are not always complete and up to date.
Another limitation is the high percentage of non-
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structured data submitted in the form of free text. The
sheer data volume and weekly growth rate make a man-
ual trial classification challenging. The problem of classi-
fying oncology related textual information is described
in work by Spasic et al. [31].
Despite these limitations we believe our analysis is
both unique and important and can provide a realistic
snapshot of interventional clinical trials using BT.
Even though, RT is a popular field among clinical scien-
tists and there is a documented increased interest during
recent years [79], this does not apply to BT. It seems that
this important discipline is being neglected in academic
circles and clinics as well. BT requires close patient con-
tact and is a hard and demanding discipline. This appears
to discourage rather than motivate the current generation
of radiation oncologists.
In this work we analyzed the current status of BT re-
search and demonstrated that several important questions
are still open. We believe that there is a lack of interest in
BT by the medical community and, as a result, research
funding is also very limited. Several important clinical
questions still remain but, unfortunately, appropriate an-
swers may not come in the foreseeable future.
Conclusion
In view of the overall incidence of diseases in which BT
has a critical role in the curative treatment, along with
several remaining clinical uncertainties, interventional
clinical trials evaluating BT procedures appear to be rare.
Appendix
Algorithm for classification of source of funding
Basically we decided that money is coming from five dif-
ferent sources:
1. Collaborative Groups
2. Industry
3. NIH
4. Academy
5. A combined public/private funding
From the clinicaltrials.gov database we have two kinds
of data registered, the primary sponsor and the collabo-
rators, based on this we identified and assigned the most
probable source of funding for each trial.
The rules used were the following:
1. Trials that had no collaborators were assigned
based on the primary sponsor alone.
2. If the primary sponsor was an academic institution
and the collaborator/s was coming from the
industry, Coll. Group or NIH, then the trial was
assigned according to the collaborator.
3. If an industry source was involved either as primary
sponsor or collaborator and the NIH or a
collaborative group as well, then the trial was
assigned as combined public/private funding
4. If no industry source was involved and the NIH
with a collaborative group were, either as primary
sponsor or collaborator, then the trial was assigned
as NIH funded.
Additional file
Additional file 1: Brachytherapy Trials grouped according to trial phase
(n: 145) (DOCX 59 kb)
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